- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01534325
Efficacy Study for SD Device
Efficacy Study of SD Device for Overweight and Obesity Treatment
Study Overview
Detailed Description
Obesity and Overweight had become the number 1 health concern of the modern world. Over 1 Billion people worldwide are overweight or obese. Those who suffer from overweight or obesity are exposed to other severe illnesses such as: diabetes, cardiovascular disease and cancer.
Only few drugs and surgeries are currently available as approved treatments for those who wish to reduce weight.
The purpose of this study is to determine whether the SD unique medical device, is effective in treatment of overweight and obesity.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Afula, Israel
- Recruiting
- Emek Medical Center
-
Contact:
- Arie Markel, MD
- Phone Number: +972-4-64943400
- Email: markel_ar@clalit.org.il
-
Principal Investigator:
- Arie Markel, MD
-
Petach Tikva, Israel, 49100
- Recruiting
- Rabin Medical Center
-
Contact:
- Dror Dicker, MD
- Phone Number: +972-3-9372426
- Email: drord@clalit.org.il
-
Principal Investigator:
- Dror Dicker, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI 30-41.99
- AGE 18-65 years
Exclusion Criteria:
- Pregnant Women,
- Type I and II diabetes,
- People with disfunctioning of thyroid gland
- Hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Study arm
The Arm who uses the real study device Daily use of SD device
|
The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference. The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance. The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss. The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements. |
|
Sham Comparator: Control Arm
Daily use of Sham comperator
|
The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference. The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance. |
|
Experimental: Staudy2 arm
Uses the under study device in a different time frames Daily use of SD device in a different time frames than of Study Arm
|
The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference. The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance. The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss. The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in Body Weight
Time Frame: once in every two weeks up to 13 weeks for each participant
|
Each participant's body weight will be measured at his/her beginning of the trial.
This measure will become the participant's body weight base-line.
Once in every 2 weeks the body weight will be taken again and will be compared to base-line and to previous body weight measures of the participant taken during the study.
|
once in every two weeks up to 13 weeks for each participant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in Waist Circumference
Time Frame: once in every two weeks up to 13 weeks for each participant
|
Each participant's Waist circumference will be measured at his/her beginning of the trial.
This measure will become the participant's Waist circumference base-line.
Once in every 2 weeks the Waist circumference will be taken again and will be compared to base-line and to previous Waist circumference measures of the participant taken during the study.
|
once in every two weeks up to 13 weeks for each participant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dror Dicker, MD, Rabin Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BeckMedical-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
National University Health System, SingaporeActive, not recruitingObesity | Overweight and/or Obesity | Overweight or Obese Adults | Overweight , ObesitySingapore
-
Carmen Lucas AbellánUniversidad Católica San Antonio de MurciaCompletedOverweight/Obesity | Overweight or Obese | Overweight or Obese Adults | Obesity and Overweight | Obese SubjectsSpain
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Empros Pharma ABNot yet recruitingOverweight or Obese | Obesity and Overweight
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
Children's Hospital Los AngelesEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight, Childhood | Overweight, InfantFrance
-
Medialis Ltd.RecruitingObesity & Overweight | Overweight (BMI > 25)United Kingdom
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Federal University of Health Science of Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Active, not recruitingObesity & Overweight | Overweight (BMI > 25)Brazil
Clinical Trials on SD
-
Queen's University, BelfastCompletedGlaucomaUnited Kingdom
-
Chuncheon Sacred Heart HospitalNot yet recruitingScapular Dyskinesis | Impingement Syndrome, ShoulderKorea, Republic of
-
Scioderm, Inc.Amicus TherapeuticsCompletedEpidermolysis BullosaUnited States
-
Theravance BiopharmaGlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
Auspex Pharmaceuticals, Inc.CompletedTOURETTE SYNDROMEUnited States
-
OptovueCompletedEyes Without Ocular PathologyUnited States
-
Paradigm TherapeuticsNot yet recruitingEpidermolysis Bullosa (EB)